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Introduction:  Osteoid  osteoma  is  a painful,  benign  bone  tumor  that  mainly  affects  young  people.  Ther-
mocoagulation  is  one  of  the  recommended  percutaneous  treatment  methods.  This  study  sought  to  assess
its efﬁcacy  and  identify  risk  factors  for osteoma  recurrence.
Methods:  Results  were  analyzed  retrospectively  for  a group  of 87  patients  treated  by thermocoagula-
tion  between  2002  and  2011.  The  recurrence  rate  was  calculated  and  analyzed  relative  to  patient  and
tumor  characteristics.  The  treatment  efﬁcacy  was  determined  and  methods  to  prevent  complications
were  analyzed.
Results: The  mean  follow-up  time  was 34 months.  The  average  patient  age  was  23 years.  There  were  seven
complications  including  three  patients  with  delayed  wound  healing,  mainly  at tibial  sites.  The  recurrence
rate  was  10.4%.  The  success  rate  for ﬁrst-line  treatment  was  89.6%  and  it  was  97.5% for  second-line
treatment.  Analysis  of  patient  characteristics  and  tumor  locations  revealed  no risk  factors  for  recurrence.
Conclusion:  Percutaneous  thermocoagulation  is  a reliable  and  effective  technique  that  provides  fast,
long-lasting  pain  relief.  However  recurrence  can  occur  even  after  the  nidus  is  completely  resected.
These  recurrences  can  be effectively  managed  by repeat  treatment.  Recent  technical  improvements  have
reduced the risk  of thermocoagulation-related  complications.
Level  of evidence:  IV.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.. Introduction
Osteoid osteoma (OO) is the most common bone-derived benign
umor. It makes up 10–12% of benign bone tumors, and 2–3% of pri-
ary bone tumors [1]. OO was ﬁrst described in 1935 by Jaffe [2,3].
t has an unusual structure and is generally less than 1 cm in diam-
ter. Histologically, 85% of osteoid osteoma cases have a nidus [4],
hich is described as a central hypervascular area surrounded by a
ard shell of bone [5]. OO mostly occurs in younger people. Patients
ypically present with disabling pain in the area of the tumor. Imag-
ng is the key to diagnosis, especially computed tomography (CT)
6]. In most cases, CT can identify the nidus and peripheral scle-
otic area. There is currently no evidence that magnetic resonance
mage (MRI) is better than CT in this application [7,8]. However,
ynamic gadolinium-enhanced MRI  slightly improves the preci-
ion of the diagnosis relative to CT scan, but not signiﬁcantly [9]. At
∗ Corresponding author. 17, rue Inkermann, 59000 Lille, France.
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877-0568/© 2014 Elsevier Masson SAS. All rights reserved.the time that Jaffe discovered OO, the gold standard treatment was
one-piece resection of the nidus [1]. This treatment is now being
performed percutaneously.
Percutaneous drill resection (PDR) is an effective technique with
a reported 85–95% success rate. [10]. PDR was used as the ﬁrst-line
treatment for OO at our facility until 2002. At that point, we pur-
chased a thermocoagulation device, which had become the gold
standard for OO treatment [11]. Through a radiofrequency (RF) gen-
erator, an alternative current heats the tissue and destroys it. The
target temperature is between 60 and 100 ◦C [12]. We  chose to use
radiofrequency to limit recurrences and complications that we  had
observed with PDR, such as skin necrosis. In particular, one patient
experienced skin necrosis at the tibia and required a secondary
sural ﬂap. We  also observed secondary cartilage damage in cases of
OO near the joint.
This retrospective study was performed in the Radiology and
Orthopedics Departments of the Lille University Hospital (CHRU)
to evaluate the efﬁcacy and failure rate of thermocoagulation
treatment and explore its limitations and complications. We  also
evaluated risk factors for recurrence and the causes of failure in this
cohort.
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ng of the guide wire. C. Introduction of the probe into the nidus.
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Fig. 2. Thermocoagulation instrumentation. A. Guide wire. B. ThermocoagulationFig. 1. A. Osteoid osteoma at the femoral head. B. Positioni
. Patients and methods
This was a single-center, single-radiologist, retrospective study.
very patient (n = 109) with osteoid osteoma who had been treated
t the Lille CHRU between January 2002 and April 2011 was eligible
or the study. The diagnosis was made by surgeons in the Orthope-
ics, Neurosurgery and Pediatric Orthopedics Surgery Departments
fter a full clinical examination and imaging assessment, which
onsisted at least of a CT scan, bone scan and MRI  in some cases.
ach patient’s record was reviewed in a multidisciplinary setting
ith at least one senior radiologist from the Musculoskeletal Imag-
ng Department present.
Six patients who underwent ﬁrst-line PDR treatment were
xcluded from the study. Sixteen patients could not be contacted
espite multiple attempts. In all, 87 patients were included in the
tudy.
Patients were admitted to the hospital on the day before the
rocedure. They were released either the day of the procedure
r the day after, following a clinical examination by the surgeon
nd an assessment of pain levels. The treatment was performed
y radiologist at the Lille CHRU Interventional Radiology Unit with
n orthopedic surgeon and anesthetist present. The procedure was
erformed under strict aseptic conditions in a sterile manner by
he referring surgeon. All procedures were performed under gen-
ral anesthesia. Depending on the size of the nidus, one of two
robes was used (5 or 10 mm activity radius). In 2009, we  changed
o a COSMAN generator (same manufacturer as the original gener-
tor, but newer model). The heating time was lengthened from 6 to
 minutes based on the manufacturer’s recommendations and the
adiologist’s experience.
After the lesion was located on CT scan (Fig. 1A), a skin marker
as used to mark the entry point for the guide wire, then the
kin incision (a few millimeters long) was performed with a no 11
calpel. The ground plate was placed on the patient’s limb and
onnected to the RF generator. A sterile ﬁeld was placed over the
urgical area. Using the most appropriate approach, a threaded K-
ire was inserted towards the nidus until it contacted bone. After
 new CT scan, the K-wire was repositioned as needed (Fig. 2A),
nd imaged again to ensure that it was perfectly centered within
he nidus (Fig. 1B). A cannulated drill bit was inserted over with
-wire to breach the bone cortex. This drilling step was  essential
n bone locations with thick cortex (femur, tibial, periosteal thick-
ning) but it was not always performed if the tumor was  located
n cancellous bone or under a thin cortex. In the latter cases, the
rocar was manually placed directly over the K-wire. Once the cor-
ex had been breached, the drill bit and guide wire were removed
nd the trocar pushed into the nidus, with continued CT scan veri-
cation. A plug was removed with the biopsy needle in all patients.
his sample was intended to histologically conﬁrm the diagnosis.
probe.
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healing treated with local wound care only; one case of injury to theFig. 3. Probe in place and connected to the RF generator.
he thermocoagulation probe (Fig. 2B) was inserted into the trocar
ntil it came into contact with the nidus (Fig. 1C) and then con-
ected to the console (Fig. 3). The device was programmed to heat
he tissue to 85 ◦C for eight minutes. In cases where neighboring tis-
ues could get burned, injections of cold, 5% glucose solution was
sed to protect the heated area by thermal isolation. At the end of
he procedure, one ﬁnal CT scan was performed to ensure the nidus
as been removed.
The 87 patients included in our study were contacted by
elephone or mail and asked to answer a questionnaire. This ques-
ionnaire took into account the duration of symptoms before the
iagnosis, effectiveness of NSAIDs and aspirin, time before the pain
isappeared after the treatment (in days), time before work-related
nd sport-related activities could be resumed (in weeks), recur-
ence rate (pain recurs after a pain-free period), treatment-related
omplications, and type of revision performed in cases of failure.
he patient’s demographics, pathology data, duration of hospital-
zation and tumor location were taken from the patient’s electronic
edical records.
The mean follow-up time was 34 months (range 6–96). The
tudy cohort consisted of 24 women and 63 men. The average
atient age was 23 years (range 5–59). Twenty-ﬁve percent of
atients were under 15 years of age, and 75% were under 30
ears of age. The most common tumor locations were the femur
n 27 cases (31%), tibia in 18 (20.7%), femoral neck in 18 (20.7%)
nd talus in six cases (6.9%). Less common locations included the
reater trochanter in 3 cases (2.5%), the elbow, knee, humerus and
capula in two patients each (2.3%) and then the spine, ﬁbula, lateral
uneiform, metatarsal, cuboid, calcaneus and pelvis in one patient
ach.
The OO was located in the lower limb in 78 patients, the upper
imb in seven patients, and in the pelvis or spine in one patient
ach. The tumor was located in the diaphysis in 41 cases (49%), the
piphysis in 11 cases (13%) and the metaphysis in 31 cases (38%).
he tumor was located in long bones in 41 cases (82%), short bones
n 15 cases (17%) and vertebrae in one case (1%). An average of 12.3
onths (range 2–48) elapsed between the appearance of pain and
he osteoid osteoma diagnosis. The NSAIDs and aspirin prescribed
efore the thermocoagulation procedure were effective in 52.7%
f patients. The median duration of hospitalization was 48 hours
range 24–72).
Of the 53 reviewed pathology summaries, 40 conﬁrmed the
iagnosis of OO. The other 13 samples were described as contain-
ng normal bone. Pathology information was not available in every
atient because not enough bone was collected in some cases toFig. 4. CT scan six months after treatment of osteoid osteoma at the femoral neck.
Nidus is no longer present; medial cortex is slightly thicker.
provide useful histology information, especially when the tumor
was located in cancellous bone.
Descriptive statistics were calculated for the above-mentioned
variables. A Kaplan-Meier survival analysis was performed to eval-
uate the main outcome, time to recurrence. Recurrence was deﬁned
as the recurrence of pain after a pain-free period. Risk factors for
recurrence were evaluated through log-rank analysis. The follow-
ing risk factors were evaluated: age, gender, type of bone, NSAIDs
efﬁcacy and pathology ﬁndings.
Some of the patients underwent additional CT scans during the
study period. In all, 24 CT scans were performed at various time
points between 6 and 48 months postoperative. These scans were
used to assess the tumor site healing (Fig. 4) and to eliminate the
possibility of recurrence in cases where the pain returned. No sta-
tistical analysis was performed on these data since CT scans were
not performed systematically during the study and the time points
were heterogeneous. The CT scan images revealed that the nidus
had completely disappeared and the treated area had become scle-
rotic in 15 cases, while the nidus had reappeared in nine cases.
These nine patients were all symptomatic at the time the CT scan
had been performed.
3. Results
There were nine recurrences in our 87 patients. This amounts
to a 10.4% recurrence rate and a ﬁrst-line treatment efﬁcacy rate
of 89.6%. All of the recurrences occurred within the ﬁrst two years
after the procedure (Fig. 5).
Of the nine patients with recurrence, four were treated by a
second thermocoagulation session and ﬁve by PDR. The second-
line treatment was  selected based on the size and location of the
tumor (Table 1). Only one patient still had pain after the secondary
treatment; she was  subsequently lost to follow-up. The second-line
treatment efﬁcacy rate was 97.5%.
There were seven complications: three cases of delayed woundlateral cutaneous femoral nerve, which regressed spontaneously;
one case of secondary talonavicular osteoarthritis; one case of
extension deﬁcit in the ﬁfth ﬁnger that required rehabilitation.
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Table 1
Summary of the various recurrences and how they were treated.
Patient Patient Location TTR (months) Treatment Indication Result
1 Scapula 18 Thermocoagulation Recurrence: nidus <1 cm on CT scan Successful
2  Femur 1 Thermocoagulation Recurrence: nidus <1 cm on CT scan Successful
3  Distal humerus 2 PDR Near joint Failed, 2nd PDR
effective
4  Femur 4 PDR Nidus size >1 cm Successful
5  Femoral neck 24 PDR Delayed recurrence Failed, no other
treatment, patient not
senn again
6  Humerus 4 PDR Physician’s decision Successful
7  Femur 8 Thermocoagulation Recurrence: Nidus <1 cm on CT scan Successful
8  Femoral neck 4 Thermocoagulat
9  Lesser trochanter 6 PDR 
TTR: time to recurrence.
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NFig. 5. Survival curve with recurrence as the end point.
one of these complications led to permanent sequelae. The patient
ho developed talonavicular osteoarthritis had previously under-
one surgery (open curettage), which is likely to have triggered the
steoarthritis.
The pain had disappears in a median of 2 days (range 1–30).
atients who become pain-free on the evening of the thermocoagu-
ation session were given a time of 1 day. The median time to return
o work or school was 15 days (range 1–90). The median time to
eturn to sports activities was 6 weeks (range 2–52). Eighty-ﬁve
ercent of patients were satisﬁed. We  found no statistical rela-
ionship between recurrence and gender, tumor location, positive
athology ﬁndings, duration of symptoms or age (Table 2).
able 2
nalysis of risk factors for recurrence.
Factor Risk Successful Failed Difference (P)
Gender F 19 4 NS
M 59 5 P = 0.072
Age  5–15 19 3 NS
15–30 40 3 P = 0.706
30+ 28 3
Location Diaphysis 37 3 NS
Metaphysis 31 4 P = 0.17
Bone Short 15 2 NS
Long 71 7 P = 0.65
Vertebra 1 0
NSAID efﬁcacy 0 31 4 NS
1 36 3 P = 0.65
Pathology No OO 11 2 NS
OO conﬁrmed 34 6 P = 0.93
S: not signiﬁcant; F: female; M:  male.ion Recurrence: Nidus <1 cm on CT scan Successful
Size >1 cm Successful
4. Discussion
The current study is one of the largest published series of OO
treatment by radiofrequency ablation. Only Rosenthal et al. [13] and
Vanderschueren et al. [14] reported on a larger number of patients
(126 and 97, respectively). Since the Lille CHRU is the only regional
hospital where percutaneous thermocoagulation is performed, our
sample was not selective.
CT-guided percutaneous radiofrequency or laser thermocoag-
ulation is approved by the French Health Authority (HAS) as a
treatment for osteoid osteoma. The treatment success rate ranges
from 76–94% [15–21]. The relevance and efﬁcacy of laser ablation
for OO treatment has also been demonstrated [22,23]. Other studies
have evaluated the relevance of percutaneous laser photocoagula-
tion [24] and reported similar results to RF ablation in terms of pain
relief and complication rate. We  have not used this technique since
the laser device is located at another facility and used to treat other
types of diseases. Our success rate was comparable to published
studies and the cohort in the current study was  one of the largest.
We decided to look at a sub-group of patients treated after 2009,
when a new thermocoagulation console was used. At that time, the
practitioner was having technical problems with the ﬁrst console,
which forced him to stop the procedure and use another technique,
namely PDR. The recurrence rate in this sub-group dropped from
12% to 7% once the new console was  used and the heating parame-
ters were adjusted. Based on manufacturer recommendations and
the radiologist’s experience, the heating time was also increased
from six to eight minutes.
Recurrence continues to be a problem and various studies have
tried to identify risk factors. Vanderschueren et al. [25] explored the
efﬁcacy criteria for thermocoagulation in a retrospective series of
110 patients. The treatment was  deemed effective if pain had com-
pletely disappeared within 15 days of the session. Success was more
likely in older patients and when the probe was  placed in multiple
positions. Cribb et al. [26] found a signiﬁcantly higher recurrence
rate in non-diaphysis locations in their 45 patient series. This ﬁnd-
ing was  not conﬁrmed in the current study, as there were no speciﬁc
factors that increased the risk of recurrence (Table 1). However,
it was  difﬁcult for us to statistically identify risk factors because
fewer than 10 cases of recurrence were available for analysis. Van-
derschueren et al. [25] showed that if the tumor was in a hard to
access position (intra-articular or deep), it is better to place multi-
ple guide wires in different directions to effectively treat the nidus.
This technique is not used by the referring physician at our facility.
The activity area of the probe used in our study was 5 or 10 mm
in diameter, depending on the volume being treated and tumor
location. Cool-tip probes have been developed that have an 18 mm
activity area. Martel et al. [27] used these probes and reported a
primary success rate of 97% and secondary success rate of 100%.
However, patients were only followed for 3–24 months.
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Vandershueren et al. [25] found that treatment duration affected
he recurrence rate. The treatment time used in our study
8 minutes at 85 ◦C) is twice as long as in most other studies. This
reatment time was chosen by the radiologist based on published
ata, the manufacturer’s advice, the console’s features and personal
xperience. The complication rate reported here was not any higher
han in other published studies and our success rate was  about the
ame.
In the current study, eight of the nine patients who  had a recur-
ence had an average pain-free period after the ﬁrst procedure of 8
ays (range 1–30). Every case of recurrence was reassessed using
T and bone scans to conﬁrm the nidus had reappeared. The ninth
atient did not experience any pain-free period and never expe-
ienced any pain relief, despite the second treatment. One of the
imitations of the current study is that different techniques were
sed to treat the recurrences. Of our nine patients with recurrences,
our were treated with a second thermocoagulation session and ﬁve
ere treated by PDR (Table 1). The pain completely disappeared in
ight of the nine patients within one day to six months. There were
o complications with either technique. Our team prefers using
DR for cases of long-term recurrence and large OO lesions because
t is reliable and effective, but it is never used as the ﬁrst-line treat-
ent.
Based on our experience, tissue burns near the tumor are the
ain complication of thermocoagulation. Preoperative imaging
ssessment is crucial for analyzing the exact position of the tumor
nd selecting a surgical approach that will minimize the risk of
njuring adjacent tissues. Finstein et al. [28] reported a case of skin
urn with 1 cm diameter necrosis after thermocoagulation of a tib-
al OO. This is the most common complication reported. Several
tudies have demonstrated that thermocoagulation has a lower risk
f complications and a lower morbidity rate than PDR or surgical
emoval, along with requiring shorter hospital stays [29,30].
In our practice, pouring cold saline over the skin during the heat-
ng period helps to limit the risk of skin burns for superﬁcial OO
ocations. Despite taking these precautions, there were still three
ases of skin burns in the current study, which did not require surgi-
al revision, only local wound care. Martel et al. [27] used a cool-tip
robe to reduce the risk of burns in adjacent tissues. Because of the
isk of osteoarthritis when the OO is near the joint, we  use a smaller
iameter probe with a smaller activity radius. Another alternative
s to protect the tissues with carbon dioxide. This is currently being
one with liver or kidney tumors treated by RF ablation [31]. This
ethod creates a protected area around the nidus and limits dam-
ge to adjacent tissues (cartilage, nerves or blood vessels).
. Conclusion
Thermocoagulation is now our gold standard treatment for
steoid osteoma treatment. The indications are well-deﬁned. The
urvival rate without recurrence in the current study was 89.6%
fter the ﬁrst thermocoagulation session. Thermocoagulation can
e used as a second-line treatment in cases of radiologically-
onﬁrmed recurrence. One of the goals of this study was  to explore
hich factors contribute to recurrence. But none of the variables
valuated were signiﬁcantly related to recurrence. Skin burns are
till the main complication, especially for tibial OO cases. How-
ver newer preventative techniques should considerably reduce
he occurrence of this type of complication.isclosure of interest
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